---
title: "Retatrutide Phase 3 Results by Dose (TRIUMPH-1 & TRIUMPH-2) | BodyHackGuide"
url: https://www.bodyhackguide.co/guides/retatrutide-phase-3-card
description: "The retatrutide phase 3 titration schedule and weight loss by dose, with and without type 2 diabetes."
lang: en
---

Skip to content

Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide)

Phase 3 · Research guide

# Retatrutide Phase 3 Research Guide

Updated October 20, 2026: added the published papers' numbers.

Every published trial, every dose, and what the data says about running it well.

Retatrutide's phase 3 results were published in September 2026, TRIUMPH-1 in NEJM and TRIUMPH-2 in The Lancet. This card puts the trial titration and results by dose in one place.

01 / TITRATION

## How the trials titrated

STEP 01

2mg

weeks 1-4

20 units

STEP 02

4mg

weeks 5-8

40 units

STEP 03

6mg

weeks 9-12

60 units

STEP 04

9mg

weeks 13-16

90 units

STEP 05

12mg

week 17 onward

120* units

Every arm started at 2mg once weekly and stepped up every four weeks. Nobody in the 12mg group reached 12mg until around week 17. Lower-dose arms stopped climbing at their target (4mg or 9mg).

Units assume 10 mg per mL on a U-100 insulin syringe. 2 mg was only ever a starting step. No trial kept anyone on 2 mg, so there's no 2 mg result.

02 / STARTING DOSE

## Start at 2 mg. The trials tested what happens if you don't.

### Nausea · titrating to 8 mg (phase 2)

17%

started at 2 mg

60%

started at 4 mg

### Vomiting · titrating to 8 mg (phase 2)

6%

started at 2 mg

26%

started at 4 mg

Same target dose, same drug. Starting one step higher roughly tripled nausea. In the 4 mg arms it doubled, 18% versus 36%. Most side effects clustered during dose increases, which is why the four-week holds exist.

03 / RESULTS

## Weight loss by dose at 80 weeks

| Dose | TRIUMPH-1 if they stayed on it | TRIUMPH-1 counting everyone who started | TRIUMPH-2 if they stayed on it | TRIUMPH-2 counting everyone who started |
| --- | --- | --- | --- | --- |
| 4mg | 19.0% | 17.6% | 12.7% | 11.9% |
| 9mg | 25.9% | 23.7% | 19.1% | 16.8% |
| 12mg | 28.3% | 25.0% | 20.8% | 18.8% |
| Placebo | 2.2% | 3.9% | 4.0% | 5.1% |

Lilly's releases lead with the number for people who stayed on the drug (the efficacy estimand). The NEJM and Lancet papers lead with the number for everyone who started, including people who stopped (the treatment-regimen estimand).

If you're insulin resistant, prediabetic or diabetic, TRIUMPH-2 is the trial that describes you. In the diabetic trial, going from 9mg to 12mg added only 1.7 points (2.0 counting everyone who started).

In TRIUMPH-1, 45.3% of the 12 mg group lost 30% or more of their body weight.

04 / TIMING

## When the weight comes off

12 mg · Week 24 **17.5%**

12 mg · Week 48 **24.2%**

12 mg · Week 80 **28.3% (25.0% counting everyone who started)**

Weeks 24 and 48 from the phase 2 trial, week 80 from TRIUMPH-1. The 12 mg curve was still dropping at week 48 with no plateau. Judge it at months, not weeks: the first 16 weeks are mostly titration.

05 / TRIALS

## Every trial so far, at the top dose

| Trial | Who was in it | People | Length | If they stayed on it | Counting everyone who started |
| --- | --- | --- | --- | --- | --- |
| Phase 2 | Obesity | 338 | 48 weeks | 24.2% | — |
| TRIUMPH-1 | Obesity, no diabetes | 2,339 | 80 weeks | 28.3% | 25.0% |
| TRIUMPH-2 | Obesity + type 2 diabetes | 1,152 | 80 weeks | 20.8% | 18.8% |
| TRIUMPH-3 | Severe obesity + heart disease | 1,949 | 80 weeks | 22.6% | — |
| TRIUMPH-4 | Obesity + knee osteoarthritis | 445 | 68 weeks | 28.7% | 23.7% |

06 / SAFETY

## Side effects, by the numbers

11-18%

quit the 12 mg dose over side effects. 11.3% in TRIUMPH-1, 18.2% in TRIUMPH-4. Placebo was 4-5%.

7-21%

dysesthesia at 12 mg, an altered skin sensation unique to this drug. 7.3% in TRIUMPH-2, 20.9% in TRIUMPH-4.

+6.7

beats per minute peak resting heart rate rise at 12 mg in phase 2, highest around week 24, easing after.

GI effects (nausea, vomiting, diarrhea, constipation) were the most common, mostly mild to moderate, and concentrated during dose increases. Lower doses dropped out less: 4.1% at 4 mg in TRIUMPH-1, below placebo.

07 / CONCENTRATION

## Reconstitution math

10 mg vial + 1 mL bacteriostatic water = 10 mg per mL. On a U-100 insulin syringe, 10 units = 1 mg. Same concentration with 20 mg + 2 mL or 30 mg + 3 mL.

| Dose | U-100 syringe units at 10 mg per mL |
| --- | --- |
| 2 mg | 20 units |
| 4 mg | 40 units |
| 6 mg | 60 units |
| 9 mg | 90 units |
| 12 mg | 120 units* |

*120 units is more than a 1 mL syringe holds, and more than one 10 mg vial contains. At the 12 mg step, a stronger mix avoids splitting: 30 mg vial + 2 mL = 15 mg per mL, so 12 mg = 80 units. Recheck the math every time you change vial size or water volume.

08 / MONITORING

## What's worth tracking

- Body weight and waist, weekly
- Resting heart rate, weekly
- A1C and fasting glucose
- Lipid panel
- CMP (kidney and liver)
- Lipase

Get a baseline before starting, then recheck around every three months. Weight, waist, A1C, glucose, blood pressure and lipids are the markers the trials themselves reported.

**Class warnings.** Approved drugs in the same class carry label warnings for pancreatitis, gallbladder disease and thyroid C-cell tumors (seen in rodents). Severe stomach pain that doesn't let up, especially spreading to the back, needs medical attention, not another week of waiting it out.

09 / STATUS

## Where it stands

1. Now
   not approved in any country
2. Q1 2027
   Lilly files the BLA with the FDA
3. +10-12 months
   standard FDA review
4. Late 2027
   earliest realistic approval

Download the 2-page PDF

## Unlock the full card

Two-page research guide. Results by dose, side effects, reconstitution math and what to track. Free.

No spam, unsubscribe anytime

For research and educational purposes only. Retatrutide is investigational and not approved for human use in any jurisdiction. Not medical advice.

BodyHackGuide (https://www.bodyhackguide.co/)

Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews.

support@bodyhackguide.co

Join our Discord: https://discord.gg/Mhq5UdRYBA
r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide

**Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology). Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure).

**Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations.

© 2026 BodyHackGuide. All rights reserved.

- Terms: https://www.bodyhackguide.co/terms
- Privacy: https://www.bodyhackguide.co/privacy

## Structured data

```json
{
  "@context": "https://schema.org",
  "@type": "Article",
  "headline": "Retatrutide Phase 3 Research Guide",
  "description": "The retatrutide phase 3 titration schedule and weight loss by dose, with and without type 2 diabetes.",
  "url": "https://www.bodyhackguide.co/guides/retatrutide-phase-3-card",
  "mainEntityOfPage": "https://www.bodyhackguide.co/guides/retatrutide-phase-3-card",
  "author": {
    "@type": "Organization",
    "name": "BHG Team"
  },
  "publisher": {
    "@type": "Organization",
    "name": "BodyHackGuide",
    "url": "https://www.bodyhackguide.co"
  },
  "isAccessibleForFree": false,
  "hasPart": {
    "@type": "WebPageElement",
    "isAccessibleForFree": false,
    "cssSelector": ".locked-content"
  }
}
```